Association between time to treatment and outcome in branch vein occlusion

Author:

Kitano Marie1,Aoki Shuichiro2,Kitamoto Kohdai2,Ueda Kohei2,Azuma Keiko2,Fujino Ryosuke2,Inoue Tatsuya3,Obata Ryo2

Affiliation:

1. JR Tokyo General Hospital

2. University of Tokyo Hospital

3. Yokohama City University

Abstract

Abstract Purpose To investigate the association between the time from onset to initial treatment and changes in visual acuity or the number of treatments in patients with branch retinal vein occlusion. Methods Thirty-nine eyes of 39 consecutive patients with untreated acute-phase BVO. The patients were initially treated with anti-vascular endothelial growth factor (VEGF) therapy and additional pro re nata therapy within six months of onset. The patients were classified according to the time from disease onset to the first treatment (group A: 28 days or less, group B: over 28 days). Results The mean age was 73 ± 8 years (53 to 88). The mean the first treatment time was 31.6 ± 17.9 days. The mean logMAR visual acuity at first treatment was 0.37 ± 0.30. The mean number of treatments was 3.1 ± 1.7. No significant association was observed between the time from onset to the first treatment and changes in the logMAR visual acuity. Patients in group A and central macular thickness at the initial visit were independently associated with the number of treatments at one year (p = 0.03 and p = 0.01, respectively). Conclusions At one year, the time between onset to the start of anti-VEGF therapy for BVO was not associated with subsequent visual acuity changes.

Publisher

Research Square Platform LLC

Reference25 articles.

1. Rogers, S.et al. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmol.117(2):313-9.e1(2010).

2. Natural history of central retinal vein occlusion: An evidence-based systematic review;McIntosh RL;Ophthalmol.,2010

3. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study;Campochiaro PA;Ophthalmol.,2014

4. Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial;Heier JS;Ophthalmol.,2012

5. Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review;Yilmaz T;Graefes Arch Clin Exp Ophthalmol.,2012

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3